NEW YORK (GenomeWeb) – LIG Biowise, a UK firm developing point-of-care molecular diagnostics to help combat antimicrobial resistance, has raised £1.8 million ($2.5 million) in a Series A funding round.

The round was led by Phoenix Bridge, a venture capital investor based in Hong Kong, and also included private investors.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.